879619-76-8

Basic information

• Product Name: N-benzyl-N-(2-phenylethyl)piperidin-4-amine
• CAS NO: 879619-76-8
• Molecular Formula: C₂₀H₂₆N₂
• Molecular Weight: 294.4338
• Mol File: 879619-76-8.mol

Chemical Properties

• Boiling Point: 431.9°C at 760 mmHg
• Flash Point: 156.3°C
• Density: 1.06g/cm³
• Vapor Pressure: 1.15E-07mmHg at 25°C
• Refractive Index: 1.593
• CAS DataBase Reference: N-benzyl-N-(2-phenylethyl)piperidin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-benzyl-N-(2-phenylethyl)piperidin-4-amine(879619-76-8)
• EPA Substance Registry System: N-benzyl-N-(2-phenylethyl)piperidin-4-amine(879619-76-8)

Safety Data

• Hazardous Substances Data: 879619-76-8(Hazardous Substances Data)

Upstream product

• 3647-71-0 N-benzyl-2-phenylethylamine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 301220-70-2 4-(N-(2-phenylethyl)amino)-1-(tert-butoxycarbonyl)piperidine 
• 100-52-7 benzaldehyde 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 122-78-1 phenylacetaldehyde 

Relevant articles and documents

Discovery and Optimization of a 4-Aminopiperidine Scaffold for Inhibition of Hepatitis C Virus Assembly

The majority of FDA-approved HCV therapeutics target the viral replicative machinery. An automated high-throughput phenotypic screen identified several small molecules as potent inhibitors of hepatitis C virus replication. Here, we disclose the discovery and optimization of a 4-aminopiperidine (4AP) scaffold targeting the assembly stages of the HCV life cycle. The original screening hit (1) demonstrates efficacy in the HCVcc assay but does not show potency prior to or during viral replication. Colocalization and infectivity studies indicate that the 4AP chemotype inhibits the assembly and release of infectious HCV. Compound 1 acts synergistically with FDA-approved direct-acting antiviral compounds Telaprevir and Daclatasvir, as well as broad spectrum antivirals Ribavirin and cyclosporin A. Following an SAR campaign, several derivatives of the 4AP series have been identified with increased potency against HCV, reduced in vitro toxicity, as well as improved in vitro and in vivo ADME properties.

QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS

The invention provides quinoline derivatives, their manufacture, pharmaceutical compositions containing them, and their use as medicaments. The active compounds of the present invention are useful for the treatment of proliferative neoplastic and nonneoplastic diseases.